Tag - PHAT

Phathom Pharmaceuticals (NASDAQ:PHAT) launched its Phase 3 trial of vonoprazan for the healing and healing maintenance of erosive esophagitis (EE). EE is a type of gastroesophageal reflux disease, or GERD, caused by...